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Abstract
 
Acute promyelocytic leukemia (APL) represents a biologic and clinically well-defined subtype of acute
nonlymphocytic leukemia with specific morphologic and karyotypic characteristics. Although secondary
leukemia and myelodysplastic syndromes (MDS) are the most frequent secondary neoplasms following
chemotherapy for acute leukemia, their development after complete remission in patients with APL is un-
common. We describe the clinical and genetic features of two APL patients who achieved CR after che-
motherapy and all-
 
trans
 
 retinoid acid treatment and subsequently developed a MDS. Therapy-related
MDS karyotype changes such as abnormalities of chromosomes 5 and 7 were found in the cytogenetic
analysis. Since 
 
TP53
 
 alteration was detected in one case, possible implications of these findings in the on-
 
set of MDS are discussed. © 2003 Elsevier Inc. All rights reserved.
 
1. Introduction
 
Secondary myelodysplastic syndrome (MDS) may result
from the exposure to DNA-damaging drugs such as alkylat-
ing agents or those targeting DNA topoisomerase II. Each
of these drug groups may induce secondary malignancies
showing various characteristics in terms of morphology, la-
tency period and cytogenetic abnormalities [1–3]. Although
these drugs are included in several acute promyelocytic leu-
kemia (APL) treatment regimens, secondary MDS develop-
ing in APL patients in complete remission (CR) are rare [4].
We describe the clinical and genetic features, emphasizing
the study of 
 
TP53
 
, in two APL patients in CR, who devel-
oped secondary MDS.
 
2. Case report
 
2.1. Case 1
 
A 70-year-old male was admitted due to asymptomatic
pancytopenia. Blood count showed Hb 8.4 g/dL, white
blood cell count 1.0 
 

 
 10
 
9
 
/L with 40% abnormal promyelo-
cytes, and platelet count 17 
 

 
 10
 
9
 
/L. Bone marrow aspira-
tion was hypercellular and showed 95% abnormal promyelo-
cytes. G-banding analysis revealed two clones: 46,XY,t(15;17)
(q21;q11) in 19 of 58 metaphases and 46,XY,inv(6)(p24q13),
t(15;17)(q21;q11) in 39 of 58 metaphases.
Reverse transcriptase polymerase chain reaction (RT-PCR)
detected the presence of 
 
PML-RARA
 
 transcript. Continuous
CR with clearance of both cytogenetic and molecular aberra-
tions was achieved after induction treatment with oral all-
 
trans
 
retinoic acid (ATRA) (45 mg/m
 
2
 
/day 
 

 
 35 days), idarubi-
cin (12 mg/m
 
2
 
/day 
 

 
 4 days), and cytosine arabinoside (Ara-C)
(100 mg/m
 
2
 
/day 
 

 
 8 days). Consolidation treatment included
two idarubicin (at 5 mg/m
 
2
 
/day 
 

 
 4 days and 12 mg/ m
 
2
 
/
 
day 
 

 
 1 day, respectively) and one mitoxantrone (10 mg/m
 
2
 
/
day 
 

 
 5 days) courses that were followed by maintenance
therapy for 2 years with daily oral 6-mercaptopurine (90 mg/
m
 
2
 
/day), weekly intramuscular methotrexate (15 mg/m
 
2
 
/day),
and oral ATRA (15-day courses every 3 months at 45 mg/m
 
2
 
/
day). Treatment was completed with persistence of CR.
However, 4 months later the patient showed Hb 8.4 g/dL,
white cell count 3.3 
 

 
 10
 
9
 
/L with 3% blast cells, and plate-
let count 104 
 

 
 10
 
9
 
/L. Bone marrow aspiration was hyper-
cellular, showing 12% blast cells and red-cell line hyperplasia
with multiple dyserythropoyetic changes in erythroblasts
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(megaloblastoid features, internuclear chromatin bridging,
abnormal mitosis, and lobulated nuclei). Flow cytometry of
bone marrow cells showed an intense reactivity with CD34,
CD13, CD33 and HLA-DR on blast cells. A new clone with
monosomies of chromosomes Y and 7 (44,X,
 

 
Y,
 

 
7) was
detected at the cytogenetic study of bone marrow in 41 of
50 metaphases. Based on hematologic, immunophenotypic,
and cytogenetic changes, the patient was diagnosed with
MDS (refractory anemia with excess blast) and he refused
any treatment other than transfusion therapy. Disease evalu-
ation after 6 months showed Hb 8.1 g/dL, white blood cell
count of 4.2 
 

 
 10
 
9
 
/L with 18% blast cells, and platelet count
of 45 
 

 
 10
 
9
 
/L. Bone marrow aspiration disclosed 25% blast
cell infiltration with the same features showed at diagnosis of
MDS. Cytogenetic analysis confirmed the presence of mono-
somies of chromosomes Y and 7. Conditions deteriorated fur-
ther and the patient died one year after MDS diagnosis.
 
2.2. Case 2
 
A 60-year-old female was admitted due to asymptomatic
pancytopenia. Blood counts at admission were as follows:
Hb 8.3 g/dL, white cell count 1.2 
 

 
 10
 
9
 
/L with 28% neutro-
phils, platelet count 7 
 

 
 10
 
9
 
/L. Peripheral blood smears
showed the presence of abnormal promyelocytes. Bone mar-
row examination was consistent with APL, and diagnosis was
confirmed by cytogenetic detection of t(15;17)(q22;q11) in
94% of studied cells, with presence of the 
 
PML-RARA
 
 tran-
script in the molecular analysis. Morphologic, cytogenetic and
molecular CR was obtained through induction treatment con-
sisting of daily oral ATRA (45 mg/m
 
2
 
/day 
 

 
 40 days) and in-
travenous idarubicin (12 mg/m
 
2
 
/day 
 

 
 4 days). Consolidation
treatment included two idarubicin courses (at 5 mg/m
 
2
 
/day 
 

 
4 days and 12 mg/m
 
2
 
/day 
 

 
 1 day, respectively) and a course
of mitoxantrone (10 mg/m
 
2
 
/day 
 

 
 5 days). Maintenance ther-
apy consisted of daily oral 6-mercaptopurine (90 mg/m
 
2
 
/day),
weekly intramuscular methotrexate (15 mg/m
 
2
 
/day) and 15-d
ATRA courses every 3 months at 45 mg/m
 
2
 
/day.
Bone marrow analysis performed after 20 months of
maintenance treatment detected a clone with 46,XX,del(5)
(q13q33). 
 
PML-RARA
 
 mRNA was still negative. The bone
marrow aspiration showed a decrease in red blood cell pre-
cursors, dysplastic changes in granulocytes, and increase in
the number of megakaryocytes, having nonlobulated nuclei.
The patient was diagnosed with secondary MDS (5q
 

 
 syn-
drome) and is currently asymptomatic without treatment.
 
3. Materials and methods
 
3.1. Cytogenetic analysis
 
Cytogenetic studies were done on unstimulated short-
term bone marrow cultures. G-banded karyotypes were de-
scribed according to International System for Human Cyto-
genetic Nomenclature (ISCN 1995).
 
3.2. Molecular analysis
 
Genomic DNA was extracted following standard procedures
from EDTA-anticoagulated peripheral blood and matched bone
marrow samples. RNA extraction and RT-PCR for 
 
PML/RARA
 
amplification were performed according to standard pro-
tocols [5].
Loss of heterozygosity (LOH) was tested through the
analysis of the following variable number of tandem repeat
(VNTR) markers: Rb1.20, a CTTT(T) repeat in intron 20 of
the retinoblastoma (
 
RB1
 
) gene and RB1.2 (D13S153), a di-
nucleotide repeat marker located in intron 2 of the 
 
RB1
 
 gene
(13q14.1) and P53IVS1, a dinucleotide repeat marker located
in intron 1 of the 
 
TP53
 
 gene (17p13.1). In all of these cases,
the analysis consisted in a PCR amplification with specific
primers with a 
 
32
 
P-end-labeled primer and subsequent analysis
of the alleles in either 6% polyacrylamide (29:1, acrylamide:
bisacrylamide) nondenaturing 35 
 

 
 45-cm gels or in 7% po-
liacrylamide Spreadex Polymer NAB gels (Elchrom Scien-
tific AG, Cham, Switzerland).
The analysis of mutation at exons 5–8 of the 
 
TP53
 
 gene
and homozygous deletion of the 
 
p16INK4
 
 gene were per-
formed as previously described [6].
 
4. Results and discussion
 
Development of MDS after treatment for APL is rare [4].
Chemotherapy could contribute to it by several mecha-
nisms. Our patients were exposed to topoisomerase II tar-
geting agents, such as anthracyclines and mitoxantrone, but
they did not show the typical chromosomal abnormalities at
11q23 or 21q22 associated with these secondary neoplasms.
However, although they did not receive alkylating agents,
their secondary cytogenetic abnormalities included losses at
chromosomes 5 and 7, that is, aberrations often described in
patients with MDS associated with exposure to alkylating
agents. The explanation for this could be that methotrexate,
6-mercaptopurine or ATRA might modify anthracycline
leukemogenesis [4].
Aside from proven effect of chemotherapy and ionizing
radiation on development of secondary malignancies, some
authors have suggested the contribution of a genetic predis-
position to the onset of secondary MDS [2]. Studies per-
formed on patients with secondary acute leukemias have
demonstrated the presence of germline mutations of the
 
TP53
 
 gene [7,8]. Since treatment with cytotoxic agents act-
ing through a 
 
p53
 
-dependent apoptotic cell death program
seems to be the main risk factor for development of second-
ary leukemia, it has been hypothesized that mutations in
DNA repair genes can lead to DNA instability, thus predis-
posing to secondary leukemia [9]. Moreover 
 
TP53
 
, 
 
RB
 
 and
the fusion protein APL-associated 
 
PML-RARA
 
 have been
recently linked by showing that the last one could inactivate
both 
 
TP53
 
 and 
 
RB
 
 pathways [10].
DNA samples from bone marrow and peripheral blood
were available for case 1, both at the moment of PML diag-
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nosis as well as at MDS development. The analysis of muta-
tion of 
 
TP53
 
 in these samples showed an altered DGGE
band pattern affecting the exon 7 of the gene in the MDS,
but not in samples from the PML at diagnosis (Fig. 1). Se-
quencing of the PCR products revealed a G to A transition
within exon 7 (TGT
 
→
 
TAT) that changes the residue num-
ber 238 of the protein from cysteine into tyrosine (C238T).
Analysis of the VNTR marker located in the intron 1 of the
 
TP53
 
 gene did not show LOH at this locus. In fact, the elec-
trophoretogram of the sequencing of the blood sample
showed the presence of the peaks corresponding to the nor-
mal (guanine) and mutant (adenine) strands with the same
intensity, whereas in the bone marrow there was a clear
overrepresentation of the mutant allele (Fig. 2). The pres-
ence of normal, non-leukemic cells in the bone marrow (re-
sidual normal hematopoiesis) and the peripheral blood of
the patient, makes the analysis of LOH by comparison of
the alleles for the P53IVS1 marker useless in this case. With
the analysis of mutation of the conserved codons of the
 
TP53
 
 gene that we performed in this study we cannot rule
out the presence of alteration in the other allele outside this
region.
This mutation has been frequently described in a wide vari-
ety of human tumors, including hematologic malignancies.
Nevertheless, to our knowledge, it has never been described
before in MDS cases following APL treatment. Although as-
sociation between 
 
TP53
 
 mutation and 5q
 

 
 deletion has been
reported [11], suggesting cooperation between loss of both
 
p53
 
 function and a putative tumor suppressor gene at 5q, we
were not able to detect any mutation at 
 
TP53
 
 in our patient
with 5q
 

 
 (case 2). Because alterations on 13q14 have been
found in a subgroup of acute leukemias resulting from MDS
transformation and occasionally in therapy-related acute
leukemia [3,12], our two cases were also screened for muta-
tions at 
 
RB1
 
 and 
 
p16INK4 
 
genes. These genes act as nega-
tive regulators of cell proliferation by blocking cell-cycle
transition from G1 into S phase through their protein prod-
ucts. Nevertheless, no abnormalities were detected at these
genes in the samples from our patients.
In conclusion, we describe two new cases of MDS after
treatment for APL. The presence of the 
 
TP53
 
 C238T muta-
tion in both the bone marrow and blood samples at MDS de-
velopment in one of the cases, but not at PML diagnosis,
suggests that the pattern of molecular alterations changes
with the development of MDS resulting in 
 
TP53
 
 pathway
abrogation.
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